JPMorgan Downgrades Merrimack Pharmaceuticals (MACK) to Neutral

October 7, 2016 7:34 AM EDT
Get Alerts MACK Hot Sheet
Price: $5.42 +2.85%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade MACK Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

JPMorgan downgraded Merrimack Pharmaceuticals (NASDAQ: MACK) from Overweight to Neutral with a price target of $7.00 (from $8.00).

For an analyst ratings summary and ratings history on Merrimack Pharmaceuticals click here. For more ratings news on Merrimack Pharmaceuticals click here.

Shares of Merrimack Pharmaceuticals closed at $5.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst PT Change, Downgrades

Related Entities

JPMorgan

Add Your Comment